The successful completion of a clinical trial often leads to increased investor confidence, which can result in a rise in the company's stock price. In this case, the AUGMENT-101 trial of Revumenib not only met its primary endpoint but was also stopped early due to efficacy, indicating a high level of success. This could potentially lead to a boost in Syndax's stock in the short term.